Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis–Pyrazoline Derivatives as Dual EGFR/BRAFV600E Inhibitors
International Journal of Molecular Sciences · 22.05.2023 · 24 (10) · 9104
DOI: 10.3390/ijms24109104 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2023. Verfasst von Lamya H Al-Wahaibi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh 11564, Saudi Arabia. Hauptthemen laut MEDLINE: Cell Proliferation, Density Functional Theory, Drug Design, ErbB Receptors. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.
Abstract (Originalsprache)
Some new Bis-pyrazoline hybrids 8–17 with dual EGFR and BRAFV600E inhibitors have been developed. The target compounds were synthesized and tested in vitro against four cancer cell lines. Compounds 12, 15, and 17 demonstrated strong antiproliferative activity with GI50 values of 1.05 µM, 1.50 µM, and 1.20 µM, respectively. Hybrids showed dual inhibition of EGFR and BRAFV600E. Compounds 12, 15, and 17 inhibited EGFR-like erlotinib and exhibited promising anticancer activity. Compound 12 is the most potent inhibitor of cancer cell proliferation and BRAFV600E. Compounds 12 and 17 induced apoptosis by increasing caspase 3, 8, and Bax levels, and resulted in the downregulation of the antiapoptotic Bcl2. The molecular docking studies verified that compounds 12, 15, and 17 have the potential to be dual EGFR/BRAFV600E inhibitors. Additionally, in silico ADMET prediction revealed that most synthesized bis-pyrazoline hybrids have low toxicity and adverse effects. DFT studies for the two most active compounds, 12 and 15, were also carried out. The values of the HOMO and LUMO energies, as well as softness and hardness, were computationally investigated using the DFT method. These findings agreed well with those of the in vitro research and molecular docking study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, College of Sciences, Princess Nourah bint Abdulrahman University, Riyadh 11564, Saudi Arabia.
- Medicinal Chemistry Department, Faculty of Pharmacy, Deraya University, Minia 61111, Egypt.
- Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Sphinx University, Assiut 71515, Egypt.
ORCID-Profile: Hesham A Abou-Zied, Alaa M Hayallah
Förderung
- Princess Nourah bint Abdulrahman University
Zitieren
APA
Al-Wahaibi, L. H., Abou-Zied, H. A., Beshr, E. A. M., Youssif, B. G. M., Hayallah, A. M., & Abdel-Aziz, M. (2023). Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis–Pyrazoline Derivatives as Dual EGFR/BRAFV600E Inhibitors. International Journal of Molecular Sciences, 24(10), 9104. https://doi.org/10.3390/ijms24109104
Vancouver
Al-Wahaibi LH, Abou-Zied HA, Beshr EAM, Youssif BGM, Hayallah AM, Abdel-Aziz M. Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis–Pyrazoline Derivatives as Dual EGFR/BRAFV600E Inhibitors. International Journal of Molecular Sciences. 2023;24(10):9104. doi:10.3390/ijms24109104
BibTeX
@article{AlWahaibi2023,
author = {Al-Wahaibi, Lamya H and Abou-Zied, Hesham A and Beshr, Eman A M and Youssif, Bahaa G M and Hayallah, Alaa M and Abdel-Aziz, Mohamed},
title = {Design, Synthesis, Antiproliferative Actions, and DFT Studies of New Bis–Pyrazoline Derivatives as Dual EGFR/BRAFV600E Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {10},
pages = {9104},
doi = {10.3390/ijms24109104}
}
EUVIMED